IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.
Diabetes mellitus type 2
IDeglira
Premix insulin
Journal
Medical archives (Sarajevo, Bosnia and Herzegovina)
ISSN: 1986-5961
Titre abrégé: Med Arch
Pays: Bosnia and Herzegovina
ID NLM: 101635337
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
10
01
2022
accepted:
09
02
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
6
7
2022
Statut:
ppublish
Résumé
IDegLira( fixed combination of GLP 1 receptor agonist and insulin) has been shown to be effective in improving the glucoregulation in patients previously treated with oral therapy as well as individual components, GLP-1 receptor agonist or basal insulin. The aim of this study is to examine the parameters of metabolic control in patients treated with IDegLira who were previously treated with premix insulin in several daily doses and to compare them with patients whose premix insulin dose was increased. The study included 100 patients who had been previously treated with two or three daily doses of premix insulin. Half of the patients were switched to IdegLira( group I), and half (group II) had their insulin dose increased according to the clinical assessment of the physician. Fasting glucose, 2h postprandial glucose, HbA1c, BMI and insulin dose were determined at baseline and at follow-up after 6 months. Patients treated with IDegLira compared to patients whose insulin dose was increased achieved significantly lower fasting glucose (p <0.001), postprandial glucose (p <0.001), HbA1c (p <0.001), BMI (p <0.001) with a significantly lower insulin dose (p <0.001). Comparison of the same parameters within the groups of patients at the beginning and after 6 months showed that patients who were switched from insulin premix to IDegLira achieved significantly lower fasting blood glucose (p <0.001), postprandial glucose (p <0.001), HbA1c (p < 0.001), BMI (p <0.001) with significantly lower insulin dose within the fixed combination (p <0.001). Patients with gradually increased insulin dose achieved significant reduction in fasting glucose (p = 0.021) and postprandial glucose (p = 0.036),but with a significantly higher insulin dose (p = 0.005). There was also a slight increase in BMI that was not statistically significant (p = 0.267). The obtained data suggest that switching patients from a complex insulin regimen to a fixed combination of basal insulin and GLP 1 receptor agonist in comparison to increases in insulin dose results in a significant improvement in fasting glucose, postprandial glucose, HbA1c, and BMI. The results were achieved with a significantly lower daily insulin dose.
Sections du résumé
Background
UNASSIGNED
IDegLira( fixed combination of GLP 1 receptor agonist and insulin) has been shown to be effective in improving the glucoregulation in patients previously treated with oral therapy as well as individual components, GLP-1 receptor agonist or basal insulin.
Objective
UNASSIGNED
The aim of this study is to examine the parameters of metabolic control in patients treated with IDegLira who were previously treated with premix insulin in several daily doses and to compare them with patients whose premix insulin dose was increased.
Methods
UNASSIGNED
The study included 100 patients who had been previously treated with two or three daily doses of premix insulin. Half of the patients were switched to IdegLira( group I), and half (group II) had their insulin dose increased according to the clinical assessment of the physician. Fasting glucose, 2h postprandial glucose, HbA1c, BMI and insulin dose were determined at baseline and at follow-up after 6 months.
Results
UNASSIGNED
Patients treated with IDegLira compared to patients whose insulin dose was increased achieved significantly lower fasting glucose (p <0.001), postprandial glucose (p <0.001), HbA1c (p <0.001), BMI (p <0.001) with a significantly lower insulin dose (p <0.001). Comparison of the same parameters within the groups of patients at the beginning and after 6 months showed that patients who were switched from insulin premix to IDegLira achieved significantly lower fasting blood glucose (p <0.001), postprandial glucose (p <0.001), HbA1c (p < 0.001), BMI (p <0.001) with significantly lower insulin dose within the fixed combination (p <0.001). Patients with gradually increased insulin dose achieved significant reduction in fasting glucose (p = 0.021) and postprandial glucose (p = 0.036),but with a significantly higher insulin dose (p = 0.005). There was also a slight increase in BMI that was not statistically significant (p = 0.267).
Conclusion
UNASSIGNED
The obtained data suggest that switching patients from a complex insulin regimen to a fixed combination of basal insulin and GLP 1 receptor agonist in comparison to increases in insulin dose results in a significant improvement in fasting glucose, postprandial glucose, HbA1c, and BMI. The results were achieved with a significantly lower daily insulin dose.
Identifiants
pubmed: 35774039
doi: 10.5455/medarh.2022.76.96-100
pmc: PMC9233474
doi:
Substances chimiques
Blood Glucose
0
Drug Combinations
0
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
IDegLira
0
Insulin
0
Insulin, Long-Acting
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-100Informations de copyright
© 2022 Amela Dizdarevic-Bostandzic, Vanja Karlovic-Beslic, Ismana Surkovic, Sefkija Balic,Tanja Dujic, Zelija Velija-Asimi, Azra Burekovic.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Diabetes Ther. 2020 Jan;11(1):331-339
pubmed: 31760599
Ther Clin Risk Manag. 2016 Mar 29;12:471-8
pubmed: 27099505
Diabetes Obes Metab. 2018 Apr;20(4):954-962
pubmed: 29205856
Diabetes Ther. 2021 Jan;12(1):197-209
pubmed: 33104959
Ther Adv Endocrinol Metab. 2018 Mar;9(3):69-79
pubmed: 29492243
Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19
pubmed: 27335581
Expert Rev Clin Pharmacol. 2017 Jun;10(6):621-632
pubmed: 28349716
Clin Diabetes. 2020 Oct;38(4):339-347
pubmed: 33132503
Postgrad Med. 2018 May;130(4):375-380
pubmed: 29521173
Diabetes Obes Metab. 2021 Jul;23(7):1445-1452
pubmed: 33651460
Diabetes Obes Metab. 2018 Jan;20(1):200-205
pubmed: 28643425
Adv Ther. 2019 Feb;36(2):265-277
pubmed: 30610613
Endocr Metab Immune Disord Drug Targets. 2021;21(4):626-646
pubmed: 32628602
Curr Med Res Opin. 2019 May;35(5):793-804
pubmed: 30370783
Adv Ther. 2019 Jan;36(1):44-58
pubmed: 30465123